Mediwelcome Healthcare Management & Technology Inc. ("Mediwelcome" or "Issuer", Stock Code: 02159.HK) commenced listing on the Main Board of the Stock Exchange of Hong Kong Limited on January 19, 2021.
Mediwelcome is the largest service provider in the Integrated Healthcare Marketing Solutions Market for cardio-cerebral-vascular diseases, or CCVDs, in China in terms of revenue in 2019, with a market share of 4.9% in the highly fragmented industry. Founded in 2000, Mediwelcome primarily provide (i) medical conference services, (ii) patient education and screening services, and (iii) marketing strategy and consulting services with the goal to address the unmet needs of each key constituent of the CCVDs healthcare ecosystem, including physicians, patients, pharmaceutical companies, medical non-governmental organizations, or NGOs, and hospitals, and to bridge the gaps among these constituents. In addition to providing integrated healthcare marketing solutions, Mediwelcome also began to offer CRO services and internet hospital services since the end of 2019.
As the PRC legal counsel of the Issuer, Global Law Office provided a full range of professional legal services throughout the IPO process of Mediwelcome with high efficiency. GLO team was led by our partners, Mr. Jinrong Liu, Mr. Chengwei Liu and Ms. Qiuqing Kang, with support from our associates Ms. Zhenzhen Zhang, Ms. Ting Liang, Ms. Zhi Li, Ms. Peizhe Sun, and Ms. Yuan Guo, etc.
-
业务领域: Private Equity & Investment Funds、Corporate / Merger & Acquisition、Outbound Investment、Tax、Capital Market
-
业务领域: Corporate / Merger & Acquisition、Private Equity & Investment Funds、Capital Market、Telecom, Media & Technology (TMT)、Life Science & Healthcare、Environment, Social & Governance (ESG)
-
业务领域: Capital Market、Corporate / Merger & Acquisition、Private Equity & Investment Funds、Life Science & Healthcare、Entertainment & Sports